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Chronic obstructive pulmonary disease (COPD) is a 
smoking-related disease that leads to progressive loss of 
lung function, debilitating symptoms and impaired quality 
of life. It imposes a considerable burden on patients, 
healthcare professionals and healthcare payers in the 
developing world - a burden that is expected to 
increase considerably as the consequences of 
continuing, and in many countries increasing, smoking 
habits become manifest. 
Despite this burden, COPD is a ‘Cinderella’ condition 
that receives limited recognition from patients and 
physicians. Considering the huge impact of COPD, 
compared with other conditions there is significant 
underfunding of research both into understanding the 
condition and into finding improved ways of treatment. 
With this low profile, it is perhaps not surprising that 
healthcare decision-makers also pay little attention to 
COPD. As a result, patients are not receiving optimal 
management, and audit studies have confirmed that care 
processes in hospital and in primary care leave much to 
be desired.Yet we know that the progression of COPD 
can be avoided by ceasing smoking; symptoms can be 
successfully alleviated and many exacerbations (including 
those requiring distressing and costly hospital admissions) 
can be prevented. 
So how can this situation be improved? A key priority 
must be raising the profile with healthcare decision- 
makers.This was the outcome of a recent meeting, held 
in Amsterdam,The Netherlands, on 24-25 January 2002 
and attended by primary and secondary care physicians, 
academic and pharmaceutical company health outcomes 
researchers, and decision-makers from healthcare 
payers. Delegates came from a number of European 
countries, as well as from Canada and the U.S.A. 
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It was apparent that nihilistic views contributed to the 
lack of awareness. Delegates considered that this could 
be addressed by greater patient understanding of the 
condition to encourage early presentation, earlier 
diagnosis by physicians, and recognition by healthcare 
payers of the benefits arising from small improvements in 
quality of life obtained with suitable interventions. 
Recent guidelines for the management of COPD were 
considered - such guidelines beg the question of how to 
define treatment success.A number of presentations at 
the meeting indicated that the success of COPD 
treatment differs with perspective - patients, physicians 
and healthcare payers have different criteria for success. 
However, a common measure emerged - the importance 
of exacerbations to patients, healthcare professionals and 
healthcare payers alike.Treatments that can reduce the 
frequency or severity of COPD exacerbations can make 
a valuable contribution. 
Obtaining evidence that will be valued and used by 
healthcare decision-makers presents another challenge in 
COPD. While randomized clinical trials are usually 
considered as the gold standard of evidence, with COPD 
they may fail to present the full picture due to exclusion of 
patients with concomitant health conditions, difficulties in 
defining appropriate health outcome measures, and 
relatively short duration compared with the prolonged 
course of the disease. Healthcare payers need to see 
evidence of treatment success applicable to the 
populations for whom they are buying care. Comparators 
need to be meaningful - that is, compared with usual 
therapy and not with placebo. Retrospective audits and 
analyses of large administrative databases that describe the 
relevant populations may provide some of the evidence 
required to justify healthcare decision-makers increasing 
their funding strategies for COPD. Finally, presenters from 
a number of healthcare systems described the limitations 
of evidence on effectiveness from the viewpoint of 
healthcare payers, some of the tools used by decision- 
makers to address these difficulties, and how healthcare 
payers decide on the therapies to be funded. 
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wider audience can help to raise the profile of COPD. 
